PUBLISHER: Grand View Research | PRODUCT CODE: 1301166
PUBLISHER: Grand View Research | PRODUCT CODE: 1301166
The global scaffold technology market size is expected to reach USD 4.92 billion by 2030, expanding at 13.87% CAGR from 2023 to 2030, according to a new study by Grand View Research, Inc. The application of 3D cell cultures is growing as they are efficient in mimicking the in-vivo physiological state of tissues for efficient representation of disease-causing microenvironmental factors.
Furthermore, increasing research focusing on the development of novel hydrogel types including injectable hydrogels, self-healing hydrogels, hybrid hydrogels, and stimuli-responsive hydrogels are expected to open new revenue generation opportunities in the coming years.
In addition, the significant advancements in regenerative medicine and tissue engineering in recent years have increased the adoption of 3D bioprinting for organ and tissue reconstruction procedures. The 3D bioprinting technique is one of the most lucrative advancements in the field of regenerative medicine which can positively affect market growth.
Numerous companies are developing new 3D bio-printed personalized scaffolds for tissue regeneration. For instance, in June 2022, 3D Systems entered a collaboration with United Therapeutics Corporation for the development of novel 3D-printed organ technologies. Similarly, nanofiber scaffolds are gaining traction due to their high surface area-to-volume ratio and their ability to mimic the fibrous structure of the natural extracellular matrix. Such scaffolds provide a suitable microenvironment for cell adhesion and proliferation, which is anticipated to boost their adoption and drive market growth during the forecast period.
Moreover, the COVID-19 pandemic remains a positive catalyst for the market for scaffold technology. Tissue engineering is extensively used for understanding virology and epidemiology, developing in-vitro model systems, and finding efficient therapeutic solutions for dealing with infection. For instance, a study published in the Advanced Healthcare Materials Journal in October 2021 demonstrated the development of a COVID-19 vaccine candidate that employs biomaterial scaffolds as recruitment sites for immune cells for the development of adaptive immunity.